Member Info for sadoldgit

Any companies that have an interest in 737 would also be aware of resistance development via the cancer using an alternative pathway at the P53 checkpoint.

The only real expert in this field is Michelle Garrett continuing research up until 2021 seeking suitable in combination compounds.

There are a few others that have researched but am not aware of any innovative breakthroughs.

Regards

The CPF granted Sierra Oncology a reduction in milestone payment after no development for 12xmonths, 12 months later SO we're claiming final trial design and 12 months after that Sierra Oncology announced they would be hading it back to the CPF.

From what info we have been given the terms of the licence are nigh identical to original agreement.

No idea as such.

Licence not yet agreed as l would deem raising of finances a prior requisite.

If it were announced there is nothing to stop a company coming in with a higher offer and shelve 737 again.

737 has vast potential especially in ano genital. Gains to be had also in BRCA1 and may be BRCA2.

In addition difficult to treat cancers such as pancreatic and HGSOC.

I am still under the firm belief that our CcT245737 would have and now more likely to knock the spots off the GSK obtained Tesaro pipeline that GSK bought for 5.1 billion dollars.

A lot of money to lose out to a competitor!

Regards

There is no shortage of interest with CHK1 inhibitors

https://www.nature.com/articles/s12276-022-00863-4

GlenFidrich.

My thinking is along the lines of people involved historically.

The involvement of Nick Glover who was CEO of Sierra Onology when 737 licenced to them

Plenty of good work carried out.

Michelle Garrett was an advisor to Sierra Oncology.

Sierra ceased development of 737 to concentrate on Momoletonib, even to the point of robbing funds that had been allocated to 737.

Nick Glover resigns.

Sierra Oncology played the game of drawing out progress to nigh 3 years. Reduced milestone payment had been agreed after a year of no development and in effect no further progress made with except 'final design stage'

Michelle Garrett had been working on developing in combo therapies with CHK1 inhibitors beyond discontinuation by Sierra Oncology.

GSK buy SO for 1.9 billion meeting their main objective for Momoletonib commercialisation.

If this as they stated was the main purpose then what may we ask were the other objectives?

At time of sale there was an uproar and nigh revolt by shareholders believing that SO had been way undervalued with consequent sake. Soon after thus Steve Dilley the CEO of SO resigned with plenty of perks ie around 1.5 million dollars.

Why did he resign?

You also have work carried out my Michelle Garrett in some form or another involving Nick Glover and 737 ( alternative resistance pathways from memory)

We,also have the 500,000 shares. At present MEI around 4 dollars a share. Market Cap of around 30 million dollars.

On addition the info given regards milestone payments is nigh an identical continuation of the licence agreement made between the CPF and Pronai Therapeutics.

There are too many coincidences here.

Regards

The tie to to MEI ìs NICK GLOVER. I have posted recently on this which gives far more incite of Sierra Oncology, Nick Glover 737, resignation of Nick Glover, Michelle Garrett involvement and of ourselves the whole debacle of SO withdrawing 737 from the shop window around a month before Nick Glovers resignation.

Regards

I flagged MEI as highly likely involved, especially the commitment of Nick Glover and also involvement 2021 in development of in combo therapy with Michelle Garrett.

100 million is circa the same as Acrivon raised.

Good finding there by Krone of raising funds, we should here news of on licence by end if March at the latest I would guess.

Regards

Regarding Beprocitonib and 1801. Exceeding 60 mg does not necessarily make 1801 better. It is also down to molar mass of the compound/molecules.

You could have two kinase inhibitors one if which contains x amount of molecules per gramme and a similar inhibitor which has 2x amount of molecules per gramme and hence twice the potency due to being half the molecular weight.

The Sareum developed molecules are patent protected. To achieve the same goal as Sareum for Tyk2 Jak 1 inhibitor it may be necessary to evolve a more complex molecule with higher molar mass and associated downsides of this approach.

I personally see no problem with 60 mg being surpassed.

The initial dosing of our SDC compounds as contained within the patent and the description thereof gave an anticipated treatment range of 12.5 to 1000 mg per day.

As far as it goes l doubt we will have SDC1801 complete phase1b before on licence or other form of finance.

Regards

74k sold 228k shown as buys.

Around 0.7p per share old money with 1801 in clinical trial si far so good and 737 developing. So for what we have it is peanuts and l would reckon if it were not for the disastrous RF funding which has had a devastating impact, we would be sitting at around 150p per share or above.

An update on 737 would not go amiss.

Makes me think that RF shorting the share.

I did post last week that l believe you will see chunky buys continue this week.

With continued buying the only option for the SP will be to increase.

With good data for 1801 expected by first half of this year it ought to propel us for a worth of around 200 million market cap.

Early stage results promising, 40% reduction in risk at this stage at least So we know longer sit at the 1 in ten success rate. Pessimistic 1 in 6 chance of success. Success is more likely achieved based on compound and attention to detail at all stages as opposed to a statistical broad and aged non updated modification that indicates greater success in later generation inhibitors that have been taken into consideration in their formulation learning from the safety concerns in early generation kinase inhibitors.

Should we take 1 to 2 billion as an approx value at late stage success and a risk rate of 20% success then before end of 1b a value that equates to 200 to 400 million. The lower value not being far away from the predicted approx 3 pounds per share.

With good results in biomarker data and very promising results at end of stage lb around 400 million market cap circa 6 pound a share.

This pertains to 1801 alone.

I am not ramping in any sense or being overly optimistic.

It is a very difficult financial climate out there and if we can secure decent funding then the above values l believe will be achieved if not exceeded.

Satisfactory data results are imperative, better than mere satisfactory are added bonus and added value.

Keep the faith

Regards

It is big news for a small company Lazarus, sareum lacks marketing expertise as they don't have millions to spend on promotion.

I'm sure the report will achieve significant interest Lazarus2

Regards

They put a lot of effort in PT after the MHRA debacle. Now as PC1954 put nicely we 'have meat on the bones' then l dare say it should not be too difficult perhaps to raise circa 6 million to progress thus removing chronic SP decline caused by the RF finance.

As for the MAD part of trial 300 mg per day should pose very little or any safety concerns as preclinical could not establish an MTD at 30x treatment dose and the therapeutic treatment dosaging regime stated by Sareum of between 12.5 and 1000 mg per day.

Preclinical with 737 was put at around max of 1000 to 1200 mg per day, and whilst ok with few adverse effects the treatment when exceeding 1000mg to 1200mg per day adverse effects increased.

So Sareums preclinical dosing assessment proved to be pretty well spot on.

6 million to guarantee advancement of 1801 to end of phase 1b with the potential it has in psoriasis alone is peanuts and also now much reduced risk.

Regards to all.

I were thinking along the same lines HbD and l think Ssreum ought to be thinking that way. For all we know they may well be.

Regards

Don't be surprised if there is similar buying next week PC1954.

We sit at 0.65p old money. Something has to give soon surely. A couple of hundred thousand shares sold and 5 million knocked off market cap.

In the past it has been on heavy drops there has been heavy buying. With exception of last couple of trades this has not been the case. More shares sold than can be sucked up by a company that has no concern for the borrower.

I will add more at these levels or lower with a Market Cap of around 22 million.

RF as we are aware have wiped over 50 million off the market cap Value on an already deflated price.

Regards to all.

1801 going well and news should follow soon of 737 developments.

Regards

Mms will be happy on trade volume.

Https://www.meipharma.com/pipeline.html

ME 344

Regards and those that have been here a while may remember the keen commitment NG had in pushing 737 to the point of stating that SRA737 may probe more commercially viable than Momoletonib. Not a happy person when 737 progress halted.

The whole affair still stinks to me.

Regards

Pretty certain that Nick Glover somewhere along the line associated with 737

https://www.linkedin.com/posts/nick-glover-5306351a_two-pronged-attack-on-dna-repair-could-kill-activity-6643904547318312961-vsJm

One if two drugs in their current pipeline address increasing effectiveness of Chk1 inhibitors

Https://www.linkedin.com/posts/nick-glover-5306351a_two-pronged-attack-on-dna-repair-could-kill-activity-6643904547318312961-vsJm

I am pretty certain thst Nick Glover has his finger in the pie with 737.

You are most welcome PC1954.

If we take May 2020 then around a month before that, that is the time that the for sale sign of 737 came down from the window so as to speak with the removal of 737 from SO website.

Nick Glover definitely had ambitions for 737 and if it is indeed MEI that is the party in question then funding will be needed. Raising of funds could be obtained by issuing new shares with a subsequent reflection of dilution on the share price.

Currently 500k shares value around 2 million dollars circa 1.5 million pounds with dilution look a tad high.

Now l would suggest whilst this is pure speculation my part, there is a potential agreement to be signed that will happen after the raising of funding. The subsequent value of the SP will follow. Possibly pushing the price down to around 2 to 2.5 dollars per share which then 500k shares would be allocated as part of the deal in the licence.

I will keep an eye on MEI closely for news updates.

It certainly adds up for me.

Regards.

9 Jan 2017 — Nick Glover, President and CEO of Sierra Oncology. "We are pleased to announce that the formal transfer of sponsorship to Sierra.

737 gave an unexpected surprise in anogenital cancers. You can glean this from a past RNS update should you care to look.

Time for a beer and a bite to eat.

Regards

Yes Nick Glover was CEO of Sierra Oncology at time of on licence!

https://www.prnewswire.com/news-releases/sierra-oncology-successfully-transfers-sponsorship-of-sra737-clinical-trials-610092045.html

Take a look at the link below gents.

https://investor.meipharma.com/news-releases/news-release-details/mei-pharma-present-design-ongoing-clinical-study-evaluating-me

MEI Pharmaceuticals look a prime candidate for 737.

Small company of circa 30 million market cap current SP around 4 dollars a share circa 7.5 million shares.

Delving into Metatastic colorectal cancers of colon, Rectum and Anus.

They have only 2 products in their pipeline and basically using in combo therapy to treat difficult to treat cancers.

It gets a little better. The key driver of SRA 737 whilst at Sierra Oncology before his resignation as CEO in 2020 was none other than Nick Glover. Surely it is not pure coincidence that Nick Glover resigned around the same time that SRA 737 development was halted by Sierra Oncology.

Nick Glover is a director of MEI Pharmaceuticals.

Nick Glover l believe was the CEO of Sierra Oncology/ Pronai Therapeutics when the onlicence of 737 took place in 2016.

Have a look at the link and see what you think.

Regards